Skip to main content
Clinical Trials/ACTRN12617000778381
ACTRN12617000778381
Completed
未知

Study assessing the safety and tolerability of an intravaginal ointment containing oleic acid in healthy female volunteers.

Zenith Technology Corporation Limited0 sites9 target enrollmentMay 29, 2017

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Zenith Technology Corporation Limited
Enrollment
9
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 29, 2017
End Date
September 6, 2017
Last Updated
4 years ago
Study Type
Interventional
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • Healthy non\-pregnant females
  • Aged between 18 and 55
  • A normal atypical or low grade intraepithelial lesion on cervical smear in the preceding 12 months
  • BMI between 19 and 30 inclusive
  • Normal, healthy individuals as determined by medical history, physical examination, ECG, blood pressure and laboratory tests
  • Able to provide written informed consent and willing to adhere to all study instructions and restrictions.

Exclusion Criteria

  • Concomitant drug therapy for any condition that is not well controlled or that might affect the vaginal mucosa.
  • Sensitivity to the study ointment
  • History of any clinically significant medical conditions
  • Clinically significant abnormality or abnormal laboratory test result found during medical screening
  • Females who are pregnant and/or are breastfeeding
  • History of alcohol or drug abuse or dependency
  • Participation in a drug study within 30 days of the start of the study
  • Volunteers for whom the Clinical Investigator believes, for any reason, that participation would not be an acceptable risk

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
Study to determine the safety and tolerability of combination therapy of TACE (Transarterial-chemoembolization) and Immunotherapy With the Autologous Killer Cell in patients with hepatocellular carcinoma: An open label study
KCT0007346Bundang CHA General Hospital10
Unknown
Phase 1
A Study to Evaluate the Safety and Tolerability of Subcutaneous Treprostinil and Pharmacokinetics of a Novel LY900014 Formulation in Healthy Japanese Subjects (I8B-JE-ITRK)Healthy
JPRN-jRCT2080223225Eli Lilly Japan K.K.
Active, not recruiting
Phase 1
A Study to Evaluate the Safety and Tolerability of JNJ-77730614 When Given as Single and Multiple Doses to Healthy Participants to Assess How Long JNJ 77730614 Stays in the Body (Pharmacokinetics) and How the Body Responds to it (Pharmacodynamics)Healthy VolunteersTherapeutic area: Diseases [C] - Immune System Diseases [C20]
CTIS2023-505684-36-00Janssen - Cilag International92
Completed
Not Applicable
STUDY TO EVALUATE THE SAFETY AND VIABILITY OF THE IMPLEMENTATION OF NT-503 IN THE VITTURAL CAVITY FOR THE TREATMENT OF SUBFOVEAL COROID NEOVASCULARIZATION (NVC) SECONDARY TO AGE-ASSOCIATED MACULAR DEGENERATION (DMAE)
PER-163-08EUROTECH,
Completed
Not Applicable
An Exploratory study on safety and tolerability of hydration using oral rehydration solution during cisplatin chemotherapyung cancer patients planned to receive two or more cycles of cisplatin chemotherapy
JPRN-UMIN000007887Department of Respiratory Medicine Kyorin Univercity Hospital60